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Abstract
Background: Circulating microRNAs (miRNAs) are a group of noncoding RNAs with promising potential as minimal
invasive biomarkers for noncommunicable diseases. However, challenges exist in the preparation of these miRNAs from
peripheral blood samples for quantification purposes. The low quality of miRNA extracts presents an obstacle.
Acknowledging the superior performance of quantitative real-time polymerase chain reaction (qPCR) as gold standard for
gene expression analysis, we conducted this study to observe the capabilities of qPCR using the Taqman® protocol in
amplifying circulating miRNAs from miRNA extracts with low purity and yield. Methods: miRNAs were extracted from
thirty-six plasma samples that were obtained from public subjects. Four selected miRNAs were quantified using the
Taqman® protocol in an integrated fluidic circuit chip that was optimized from a previous study. The amplification graph
and Cq values were obtained to observe any abnormal amplification signs and expression levels, respectively. Results: The
qualitative observation of the amplification of the four miRNAs showed no sign of abnormality, thereby indicating the
successful amplification of the miRNAs without enzymatic inhibition. Furthermore, the miRNAs were quantified in high
expression levels. Conclusion: The circulating miRNA extracts with low purity and yield were practical for the study of
circulating miRNA expression based on the Taqman® protocol as the method of detection.
Keywords: amplification, circulating, isolation and purification, microRNA, quantitative real-time polymerase chain
reaction

its chemical structure, biogenesis, functions, and clinical
utility for diagnostic, prognostic, and therapeutic
purposes.1–3 miRNA is a class of short noncoding RNAs
that mainly regulate protein expression at the posttranscriptional level in the cytoplasmic region, and

Introduction
First found in Caenorhabditis elegans in Victor Ambro's
laboratory in 1993, microRNA (miRNA) has been
extensively studied, with current research encompassing
147
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growing evidence suggests that it may also regulate
gene expression at the pre-transcriptional level by
binding to the gene promoters in nuclear regions.4–6
miRNAs are found not only in intracellular environments
but also in extracellular environments, such as blood
and saliva.7,8 miRNAs are transported out from cells
mainly by exocytosis, and they are either encapsulated
in or free from vesicles for cell–cell communication.9
A growing body of evidence demonstrates the
promising utility of circulating miRNAs as biomarkers
of noncommunicable diseases, but their pre-analytical
processing and detection still suffer from several
challenges.10 Despite the good number of scientific
publications about issues and improvements in certain
pre-analytical parts for the study of circulating miRNAs,
such as sample processing and circulating miRNA
extraction, no study has reported the suitability of
utilizing circulating miRNA extracts with low purity
and yield in detecting miRNA using quantitative realtime polymerase chain reaction (qPCR).11–14 qPCR is a
gold standard for gene expression analysis because of its
superior specificity and sensitivity in detecting
diseases.15,16 The improvement in qPCR has made this
method capable of detecting DNA and RNA in low
concentration samples.17,18 Moret et al.19 expressed their
concern about the use of plasma samples for miRNA
detection as such samples could affect qPCR efficiency
through their low level, short length, and carried-over
inhibitors during extraction. Nevertheless, no study has
reported the hampered efficiency of qPCR by using
such miRNA extracts. Moret et al.19 did test the
detection efficiency of circulating miRNA extracts, but
they used the microarray method of detection and not
qPCR. Through the revolutions in qPCR, this research
tool can now compete with commercial high-throughput
platforms, such as microarrays and next-generation
sequencing, in terms of detecting the abundance of
genes simultaneously even with a low input of starting
materials.20,21 In the present study, we showed that the
detection of three circulating miRNAs in miRNA
extracts with low purity and yield was possible by using
qPCR. Moreover, the expression of these miRNAs was
high in miRNA extracts with low purity and yield.
Hence, qPCR is suitable for the study of circulating
miRNA expression.

Methods
Subject recruitment. The protocol was reviewed and
approved by the IIUM Research Ethics Committee
(IREC 457), Human Research Ethics Committee of
Universiti Sains Malaysia (USM/JEPeM/16010032),
and Medical Review and Ethics Committee (NMRR151976-27156). Thirty-six subjects in the Pahang and
Kelantan states of Malaysia were recruited randomly.
Signed consent forms were obtained from the subjects
who volunteered to participate in the study. The personal
Makara J Health Res.

details of the subjects were kept confidential, and their
names were replaced with identification numbers. During
the recruitment, demographic data were taken from each
participant.
Plasma sample collection. Exactly 10 mL of blood was
drawn from the antecubital vein of each subject by
using a syringe and 21-gauge needle. The blood was
collected into a blood collection tube containing
ethylenediaminetetraacetic acid, kept in ice, and
processed within 4 h after collection. Plasma was
obtained by centrifuging the blood for 15 min at 1200 ×
g at room temperature and then stored in a freezer at
−80 ℃ until further use.22
Circulating miRNA extraction. The miRNAs from the
plasma samples were extracted using the NucleoSpin®
miRNA plasma kit (Macherey-Nagel, Düren, Germany)
according to the manufacturer's protocol with a few
modifications by Wozniak et al.23 In the miRNA
extraction, the plasma was subjected to Proteinase K
treatment to digest protein and thereby increase the
miRNA yield. The supernatant obtained after the
Proteinase K treatment was spiked-in with 10 pmol
mirVana™ ath-miR-159a mimic (Thermo Fisher
Scientific, Massachusetts, United States) for quality
control of the miRNA isolation efficiency. Exactly 2 μg
of glycogen (Roche, Basel, Switzerland) was then added
as an RNA carrier to improve miRNA binding to the
NucleoSpin® miRNA column. DNA digestion was
performed after filtration of the supernatant to prevent
the interference of co-purified DNA during the
quantification of miRNAs using 50 µL of rDNase.
Then, the column was washed with the washing buffers
of the kit prior to elution using RNase-free water that
was preheated to 56 ℃ to improve the elution
efficiency. The purity and RNA yield of the miRNA
extracts were measured spectrophotometrically using
NanoDrop™ 1000 (Thermo Fisher Scientific,
Massachusetts, United States).
Reverse transcription reaction. In reverse transcription
(RT) reaction, fixed volume was used as the starting
material rather than the equal quantity of miRNA as it is
recommended for samples that could not be quantified
spectrophotometrically, such as plasma.24,25 In addition to
the spike-in miRNA (i.e., ath-miR-159a), three
circulating miRNAs previously reported to be present in
peripheral blood, namely, hsa-miR-16, hsa-miR-93, and
hsa-miR-191, were used for detection.26–31
The master mix for RT reaction was prepared by mixing
37 μL Multiscribe™ RT enzyme (50 U/μL), 37 μL 10×
RT buffer, 7.4 μL dNTP mix (100 mM), 5.55 μL RNase
inhibitor (20 U/μL), and 111 μL 0.156× RT primer pool
(consisting of ath-miR-159a, hsa-miR-16, hsa-miR-93,
and hsa-miR-191). Then, 5.35 μL of the RT master mix
was mixed with 4.65 μL of samples in PCR tubes,
December 2020 | Vol. 24 | No. 3
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including 4.65 μL of nuclease-free water for no template
control (NTC) for RT reaction (NTC RT). The RT
reaction was performed in a ProFlex PCR System
(Applied Biosystems, California, United States) with the
following settings: 16 ℃ for 30 min for the first stage,
followed by 42 ℃ for 30 min and 85 ℃ for 5 min. Once
the reaction was completed, the RT products were
diluted with nuclease-free water with a ratio of 1:4.
Preamplification reaction. The master mix for
preamplification reaction was prepared by mixing 185
μL Taqman® PreAmp Master Mix (2×) and 92.5 μL
0.2× preamplification primer pool (consisting of athmiR-159a, hsa-miR-16, hsa-miR-93, and hsa-miR-191).
Then, 7.5 μL of the master mix was mixed with 2.5 μL
of the diluted RT products, including the NTC RT
product to make an NTC for preamplification (NTC
PA), in PCR tubes. The preamplification reaction was
performed in the ProFlex PCR System (Applied
Biosystems, California, United States) with the
following settings: 95 ℃ for 10 min for the first stage,
followed by 95 ℃ for 15s, and 60 ℃ for 4 min in the
second stage for 16 cycles. Once the reaction was
completed, the preamplification products were diluted
with nuclease-free water with a ratio of 1:5.
Quantitative real-time polymerase chain reaction. A
Dynamic Array™ integrated fluidic circuit (IFC) chip
(Fluidigm, California, United States) was used for the
qPCR assays. Before preparing the qPCR assay, control
line fluid was injected into the accumulators on the IFC
chip, followed by loading into the IFC controller
(Fluidigm, California, United States). The “Prime”
script was subsequently run to pump the fluid into the
microfluidic channels of the IFC chip.
For the qPCR procedure, two 96-well plates were used
as sample and assay plates to prepare the master mix
preparation. For the sample plate, a master mix of
premixed samples was prepared for 37 reactions by
mixing 92.5 μL of Taqman® Universal Master Mix (2×)
with 9.25 μL of GE sample loading reagent in a 1.5 mL
tube. Then, 4.4 μL of the master mix was mixed with
3.6 μL of the diluted preamp products, including the
NTC PA product to make an NTC for PCR (NTC PCR),
in each well of the sample plate. For the assay plate, the
assay master mix was prepared for triplicate reactions
by mixing 7.5 μL of Taqman® Assay real-time primer
(20×) with 7.5 μL of assay loading reagent in a qPCR
tube for each primer.
In using the IFC chip, either the sample inlets or the
assay inlets need to be replicated. Once the samples and
assays are pumped from their inlets into a reaction
chamber using the IFC controller (Fluidigm, California,
United States), replication occurs in the reaction
chamber. In the current study, the assays were replicated
thrice. Exactly 5 μL of the sample master mix from the
Makara J Health Res.
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sample plate was dispensed in the sample inlets on the
chip. Then, 5 μL of the assay master mix was dispensed
in the assay inlets in triplicate. The chip was
subsequently loaded into the IFC controller (Fluidigm,
California, United States), and the “Load Mix” script
was run to pump the samples and assays to the reaction
chamber. The chip was then loaded into a Biomark™
HD system (Fluidigm, California, United States) for
qPCR based on the default protocol.
Data collection and calculation. The graphs of
amplification curves were obtained by importing the
raw data from the Biomark™ HD system (Fluidigm,
California, United States) to the Fluidigm Real-Time
PCR Analysis software (Fluidigm, California, United
States). The same software was also used to calculate
Cq under auto-threshold and auto-baseline settings prior
to further analyses. The mean Cq, standard deviation
(SD), and coefficient of variation (CV) were calculated
using Microsoft Excel.

Results
Table 1 summarizes the demographic data of the
subjects. The mean age was 50.4 ± 15.3.
Table 1. Descriptive demographic data of subjects
Variables
Sex
Male
Female
Race
Malay
Chinese
Aborigine

Frequency
26
10
28
7
1

Purity and yield of plasma miRNA extracts. The
spectrophotometric results (Table 2) showed the
presence of miRNAs with low purity and yield in the
miRNA extracts. As observed in the absorbance graph
in Figure 1, an apparent high peak emerged around a
wavelength of 230 nm, and it indicated the high
concentration of contaminants that absorbed light at
such wavelength. Meanwhile, the peaks at 280 nm were
not as apparent as the peak at 230 nm. Although all
miRNA extracts showed low values for the 260/230 and
260/280 ratios, the trends reflected in the graph were
consistent across the samples.
Amplification curves of ath-miR-159, hsa-miR-16,
hsa-miR-93, and hsa-miR-191. The amplification
curves of ath-miR-159a, hsa-miR-16, hsa-miR-93, and
hsa-miR-191 in all the plasma miRNA extracts showed
the expected normal sigmoid property. Moreover, no
abnormality in the shape of the amplification curves was
observed (Figure 2). No hook effect-like shape, an
abnormal shape for a qPCR amplification curve, was
December 2020 | Vol. 24 | No. 3
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observed in the amplification curves, thereby indicating
the successful amplification of miRNAs in the
experiment. These results indicated that the circulating
miRNA extracts were of good quality and could be used
for qPCR applications.
Cq data of ath-miR-159, hsa-miR-16, hsa-miR-93,
and hsa-miR-191. The Cq data of the four miRNAs in
the plasma miRNA extracts are presented in Table 3 and

Figure 3. The qPCR results showed a high expression of
all the tested miRNAs in all the plasma miRNA
extracts. Moreover, the SD for all miRNAs was not too
large to show outliers that might indicate interference
during the reaction. Table 3 shows that the CV of athmiR-159a was lower than those of hsa-miR-16, hsamiR-93, and hsa-miR-191. The spike-in of ath-miR159a into the samples was conducted consistently across
the samples.

Table 2. Purity and miRNA yield values of plasma samples for validation

Makara J Health Res.

Sample

260/230 ratio

260/280 ratio

CP5

0.17

0.95

miRNA yield
(ng/µL)
3.2

CP9

0.14

0.94

4.8

CP17

0.18

0.86

4.3

CP18

0.10

0.54

2.7

CP19

0.13

0.75

4.5

CP21

0.15

0.75

2.9

CP22

0.21

0.94

6.3

CP23

0.15

0.78

8.8

CP24

0.16

0.79

2.0

CP25

0.14

0.93

5.3

CP29

0.10

0.58

1.1

CP30

0.07

0.87

1.8

CP31

0.19

0.83

4.5

CP32

0.20

1.01

8.6

CP35

0.20

1.11

6.3

CP37

0.19

1.06

7.9

CP40

0.22

1.08

9.5

CP43

0.12

0.61

2.6

CP49

0.14

0.69

2.2

CP50

0.13

0.65

2.1

CP52

0.18

0.80

3.4

CP51

0.12

0.64

2.2

CP53

0.02

0.54

0.9

CP57

0.12

0.68

5.6

CP58

0.17

0.81

5.3

CP59

0.13

0.85

4.8

CP60

0.13

0.71

3.1

CP64

0.13

0.67

2.9

CP66

0.17

0.88

5.6

CP74

0.18

1.22

3.2

CK7

0.23

0.97

8.0

CK9

0.08

0.77

2.3

CK10

0.15

0.83

2.0

CK11

0.13

0.72

2.4

CK12

0.18

0.72

4.8

CK18

0.15

0.72

4.3
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Figure 1. Example of absorbance graph produced by NanoDrop™ 1000 for miRNA extracts from plasma samples in the current
study

Amplification curves from the current study

Figure 2. Amplification curves of (A) ath-miR-159a, (B) hsa-miR-16, (C) hsa-miR-93, and (D) hsa-miR-191

Makara J Health Res.
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Table 3. Cq data for ath-miR-159a, hsa-miR-16, hsa-miR-93, and hsa-miR-191
miRNAs

Cq (Mean ± SD)

CV

ath-miR-159a

6.765 ± 0.656

0.097

hsa-miR-16

6.739 ± 1.077

0.160

hsa-miR-93

12.045 ± 1.490

0.124

hsa-miR-191
12.981 ± 1.951
0.150
Cq values of ath-miR-159a, hsa-miR-16, hsa-miR-93, and hsa-miR-191

Figure 3. Box plots for ath-miR-159a, hsa-miR-16, hsa-miR-93, and hsa-miR-191. Cq: quantification cycle

Discussion
Low purity plasma RNA extracts are a cause for
concern because blood samples, especially those drawn
from patients, are precious. Not all patients are willing
to donate blood while sick. Moreover, blood withdrawal
from elderly patients is not as easy as that from younger
patients. Given the low miRNA level in peripheral
blood, such blood samples may become highly
contaminated with organic and inorganic materials, as
determined by spectrophotometry measurement, after
extraction. Hence, samples are discarded as they are
presumed not suitable for some laboratory procedures.
Owing to the superior performance of qPCR as a gold
standard for gene expression analysis, we were
interested to observe the capability of qPCR in detecting
miRNA in miRNA extracts with low purity and yield.
In the current study, all miRNA extracts from the
plasma samples showed miRNAs with low purity and
yield. The 260/230 and 260/280 ratios were extremely
low, and they commonly indicate the presence of
contaminants in higher amounts than the miRNAs.32,33
Generally, this type of RNA extracts is unacceptable for
several downstream applications, such as qPCR,
microarray, and sequencing; hence, they were excluded
from the study. The contaminants in RNA extracts,
mainly organic substances, may be carried from samples
or extraction reagents. These contaminants may cause
Makara J Health Res.

RNA degradation, as well as mechanistic and enzymatic
inhibition during RT or PCR steps, and thereby hamper
qPCR.34–36 Among the recognized organic PCR
contaminants that are commonly present in DNA or
RNA extracts from blood samples are salts; phenol;
ethanol; and variety of proteins, such as hemoglobin and
immunoglobulin G, which may originate from samples
or extraction reagents.36,37 Apart from the inhibitory
nature of certain substances on PCR, some substances
(e.g., sodium hydroxide and ethylenediaminetetraacetic
acid [EDTA]) only cause the inhibitory effect when they
reach certain concentrations.38 Generally, these PCR
inhibitors interfere with the reaction by targeting DNA
polymerase, nucleic acids, and fluorophores.34–36
The absorbance graphs produced by NanoDrop™ 1000
from the miRNA extracts in this study were consistent
with the graph by NanoDrop from a study by Moret et
al.19, who assessed the quality of plasma miRNA
extracts from several miRNA extraction kits and
indirectly validated the quality of circulating miRNA
extracts. The apparent high peak at the 230 nm
wavelength in the current study indicated the high
concentration of contaminants that absorbed light at
such wavelength, such as proteins, guanidine salt,
EDTA, carbohydrates, lipids, and phenols.33,39 The
possible contaminants in the plasma miRNA extracts
could have mainly originated from the sampling
procedure, in which EDTA was used as the antiDecember 2020 | Vol. 24 | No. 3
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coagulant; and from the miRNA isolation procedure, in
which glycogen and guanidine were used as the RNA
carrier and in miRNA isolation reagents, respectively.
However, protein contamination was supposed to be a
minor issue in the study as the Proteinase K digestion
treatment was implemented in the miRNA isolation
procedure to reduce contamination.
The consistent trends reflected in the graphs across the
samples made us speculate that they may be due to the
nature of the samples. Furthermore, the results of this
work are consistent with those of Moret et al.19. The
generally low concentration of RNAs in peripheral
blood, including miRNAs, as shown in the spectrometry
results, could explain the purity of our miRNA extracts
being as low as the purity of RNAs measured by
NanoDrop™ 1000 using the ratio of nucleic acids to
possible contaminants.40–42 Therefore, a low numerator
(260 for RNA) and a high denominator (230 and 280 for
possible contaminants) would mathematically yield low
260/230 and 260/280 ratios. This result was in
agreement with that of El-Khoury et al.25, who reported
that a low RNA concentration explains the low 260/230
and 260/280 ratios in low yield RNA extracts. Previous
research has emphasized the inappropriateness of
quantifying extracts with low nucleic acid concentration
using spectrophotometry.25,43,44 Furthermore, the miRNA
isolation kit used in our work has been reported to result
in better miRNA isolation performance than other
commercial miRNA isolation kits.45,46 The merit of such
miRNA isolation kit is indisputable, and the isolated
miRNAs are of good quality and applicable to
downstream procedures. Hence, the suitability of miRNA
extracts with low purity for qPCR procedures is worth
assessing before considering the rejection of samples.
A previous study by El-Khoury et al.25 reported the
usability of miRNA extracts with low purity and yield
for qPCR applications using quantitative analysis.
Different from the previous study, the current study
attempted to share the results qualitatively by observing
the shapes of the qPCR amplification curves of the
specific miRNAs in our plasma miRNA extracts.
Relative to Cq values, which were considered in the
work of El-Khoury et al.25, amplification curves
facilitate the direct assessment of the efficiency of
qPCR based on their abnormalities. The current study
demonstrated the capability of qPCR in efficiently
amplifying and detecting ath-miR-159a, hsa-miR-16,
hsa-miR-93, and hsa-miR-191 in miRNA extracts with
low purity and yield from plasma samples on the basis
of the normal sigmoid curves with no abnormal shapes,
such as a hook effect-like shape. To the best of our
knowledge, the hook effect-like shape (black-colored
sigmoid curve in Figure 4) is among the reported
abnormalities in the shapes of amplification curves,
other than the absence of amplification signals.47 This
phenomenon occurs at the late cycle of PCR, in which
Makara J Health Res.

Figure 4. Hook effect-like shape of qPCR amplification
curve.49 RFU: relative fluorescence unit

the detection probes compete with the amplicons
because of the increased concentration of the amplicon's
nature at the late cycle and the consequent reduction in
fluorescent signal detection.47,48 This abnormal shape is
an indicator of a failed experiment and can be subjected
for exclusion from the study.47 As shown in Figure 2, no
hook effect-like shape was observed in the amplification
curves of this study, thus indicating the successful
amplification of miRNAs in the experiment.
The current study also reported the quantitative data of
Cq values for each circulating miRNA. Overall, the Cq
data showed that the circulating miRNAs measured in
this study were high. The higher CV of the spike-in
control, which was ath-miR-159a, in comparison with
that of the circulating miRNAs indicated that the
experiment was conducted well and that the qPCR
reaction was efficient. The higher SD for hsa-miR-16,
hsa-miR-93, and hsa-miR-191 in comparison with that
for ath-miR-159a was due to the heterogeneous
expression of the three miRNAs as endogenous
miRNAs in human samples. The heterogeneity in
human population samples and the release of miRNAs
into peripheral blood were described by Wang et al.49
and Sohel.10
Among the factors that contributed to the successful
detection of circulating miRNAs in miRNA extracts
with low purity and yield in this study was the use of
the Taqman® protocol as a specific and sensitive
detection method.45,50 The design features of this
protocol include the use of the stem-loop primer in the
RT step, the addition of a preamplification step to preamplify RT products, and the use of a hydrolysis probe
as detection chemistry during the qPCR step. 50,51 The
stem-loop RT primer used in the RT step was
demonstrated to be capable of discriminating the
precursor and mature miRNAs and the related
miRNAs that may differ by one nucleotide. 52,53 This
factor was deemed to have contributed to the
specificity of the Taqman® protocol. 53 The stem-loop
RT primer was also highly sensitive in quantifying
December 2020 | Vol. 24 | No. 3
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low-abundance miRNAs.52 The application of the
preamplification step in detecting low-abundance
miRNAs has been proven to increase the sensitivity of
detection without introducing any systemic bias in the
analysis of miRNA expression. 54 The preamplification
step has also been optimized with an IFC chip to
increase the sensitivity of detection for low-abundance
miRNAs; hence, the step is considered suitable for
circulating miRNA detection. 45,55 Meanwhile, the use
of a hydrolysis probe, that is, the Taqman® probe, also
contributes to the successful detection of lowabundance miRNAs due because of the sensitivity and
specificity of the Taqman® probe in detecting DNA
and RNA.56–58 This detection probe has gained
popularity among researchers because of its specificity
in annealing to specific targets and its applicability to
multiplex assays. 59,60 Considering the aforementioned
body of evidence, we suggest that the Taqman®
protocol is helpful in the detection of circulating
miRNAs in miRNA extracts with low purity and yield.
We successfully demonstrated that with the use of the
Taqman® protocol, circulating miRNAs can be amplified
in miRNA extracts with low purity and yield without
any enzymatic inhibition. The study employed an IFC
chip as the microfluidic channel platform and used a
small reaction volume of assay to test the qPCR
amplification. Indirectly, the present study also showed
that the circulating miRNAs in miRNA extracts with
low purity and yield could be detected with high
expression using a small reaction volume of qPCR assay
that is commonly used in high-throughput platforms,
provided that the Taqman® protocol is used. Regarding
the quantity of RNA materials for RT reaction, a fixed
volume of miRNA extracts was recommended.24,25 Thus,
miRNA extracts with low purity and yield are suitable for
high-throughput platforms that use a small volume of
qPCR assay and a high volume of single qPCR assay.

Conclusion
The evidence provided in this study builds a new
perspective on the detection of circulating miRNAs in
extracts with low purity and yield using qPCR. The
unnecessary rejection of circulating miRNA extracts
from any study because of their unsatisfactory purity
and inadequate RNA yield could be avoided with
consideration of how precious blood samples are.
However, the current study employed one commercial
miRNA extraction kit only. The test on several commonly
used extraction kits in circulating miRNA research should
generate a relatively generalized result on the application
of qPCR for miRNA extracts with low purity and yield
from different extraction kits. As no standardized
miRNA extraction method for biofluid samples has
been developed, the findings of our work are expected
to aid, at least partly, in improving commercially
available miRNA extraction methods and kits.
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